Tao Bo, Jiang Enyan, Zhao Yuan, Xu Zhangxiao, Yang Juan, Wang Lijun
Department of Urology, Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Kunming, 650300, China.
Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, China.
World J Urol. 2025 May 13;43(1):299. doi: 10.1007/s00345-025-05663-9.
To compare the efficacy of mirabegron and doxazosin in alleviating ureteral stent-related symptoms and sexual dysfunction.
This study included 107 patients who provided informed consent and underwent transurethral ureteral lithotripsy with ureteral stent placement between January 2023 and December 2023. Patients were randomized into two groups receiving either mirabegron (50 mg/day) or doxazosin (4 mg/day). The Ureteral Stent Symptom Questionnaire (USSQ) scores and adverse drug reactions were recorded at baseline (ureteral stent placement), 2 weeks (ureteral stent removal), and 4 weeks (2 weeks after stent removal). The trial was registered with the Chinese Clinical Trial Registry (ChiCTR2500095161).
At 2 weeks, the mirabegron group showed a greater improvement in pain during intercourse compared to the doxazosin group (0.379 ± 0.186; p = 0.043). This improvement persisted at 4 weeks (0.363 ± 0.186). No significant differences were observed in sexual satisfaction scores between the groups at either time point (2 weeks: 0.175 ± 0.186, p = 0.350; 4 weeks: 0.157 ± 0.186, p = 0.401). Subgroup analysis revealed that mirabegron provided greater relief of pain during intercourse in women compared to doxazosin (OR = 14.40, 95% CI 1.53-135.51, p = 0.020). Additionally, women in the doxazosin group reported significantly lower sexual satisfaction compared to the mirabegron group (OR = 42.00, 95% CI 2.41-825.71, p = 0.014).
Mirabegron and doxazosin demonstrated similar efficacy in relieving ureteral stent-related symptoms. However, mirabegron offered a clear advantage in improving female sexual function, particularly regarding pain during intercourse and overall satisfaction.
比较米拉贝隆和多沙唑嗪在缓解输尿管支架相关症状和性功能障碍方面的疗效。
本研究纳入了107例在2023年1月至2023年12月期间提供知情同意并接受经尿道输尿管碎石术及输尿管支架置入术的患者。患者被随机分为两组，分别接受米拉贝隆（50毫克/天）或多沙唑嗪（4毫克/天）治疗。在基线（输尿管支架置入时）、2周（输尿管支架取出时）和4周（支架取出后2周）记录输尿管支架症状问卷（USSQ）评分和药物不良反应。该试验已在中国临床试验注册中心注册（ChiCTR2500095161）。
在2周时，米拉贝隆组在性交时疼痛方面的改善程度高于多沙唑嗪组（0.379±0.186；p=0.043）。这种改善在4周时持续存在（0.363±0.186）。在两个时间点，两组之间的性满意度评分均未观察到显著差异（2周：0.175±0.186，p=0.350；4周：0.157±0.186，p=0.401）。亚组分析显示，与多沙唑嗪相比，米拉贝隆在女性性交时疼痛缓解方面效果更佳（OR=14.40，95%CI 1.53-135.51，p=0.020）。此外，多沙唑嗪组女性报告的性满意度显著低于米拉贝隆组（OR=42.00，95%CI 2.41-825.71，p=0.014）。
米拉贝隆和多沙唑嗪在缓解输尿管支架相关症状方面疗效相似。然而，米拉贝隆在改善女性性功能方面具有明显优势，尤其是在性交时疼痛和总体满意度方面。
